FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912103211> ?p ?o ?g. }

• W2912103211 endingPage "2300" @default.
• W2912103211 startingPage "2292" @default.
• W2912103211 abstract "Background: Guidelines caution against the use of non–vitamin K antagonist oral anticoagulants in patients with extremely high (>120 kg) or low (≤60 kg) body weight because of a lack of data in these populations. Methods: In a post hoc analysis of ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; n=18 201), a randomized trial comparing apixaban with warfarin for the prevention of stroke in patients with atrial fibrillation, we estimated the randomized treatment effect (apixaban versus warfarin) stratified by body weight (≤60, >60–120, >120 kg) using a Cox regression model and tested the interaction between body weight and randomized treatment. The primary efficacy and safety outcomes were stroke or systemic embolism and major bleeding. Results: Of the 18 139 patients with available weight and outcomes data, 1985 (10.9%) were in the low-weight group (≤60 kg), 15 172 (83.6%) were in the midrange weight group (>60–120 kg), and 982 (5.4%) were in the high-weight group (>120 kg). The treatment effect of apixaban versus warfarin for the efficacy outcomes of stroke/systemic embolism, all-cause death, or myocardial infarction was consistent across the weight spectrum (interaction P value>0.05). For major bleeding, apixaban had a better safety profile than warfarin in all weight categories and even showed a greater relative risk reduction in patients in the low (≤60 kg; HR, 0.55; 95% CI, 0.36–0.82) and midrange (>60–120 kg) weight groups (HR, 0.71; 95% CI, 0.61–0.83; interaction P value=0.016). Conclusions: Our findings provide evidence that apixaban is efficacious and safe across the spectrum of weight, including in low- (≤60 kg) and high-weight patients (>120 kg). The superiority on efficacy and safety outcomes of apixaban compared with warfarin persists across weight groups, with even greater reductions in major bleeding in patients with atrial fibrillation with low to normal weight as compared with high weight. The superiority of apixaban over warfarin in regard to efficacy and safety for stroke prevention seems to be similar in patients with atrial fibrillation across the spectrum of weight, including in low- and very high–weight patients. Thus, apixaban appears to be appropriate for patients with atrial fibrillation irrespective of body weight. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00412984." @default.
• W2912103211 created "2019-02-21" @default.
• W2912103211 creator A5006527198 @default.
• W2912103211 creator A5009430890 @default.
• W2912103211 creator A5014449865 @default.
• W2912103211 creator A5015603706 @default.
• W2912103211 creator A5027138068 @default.
• W2912103211 creator A5036973667 @default.
• W2912103211 creator A5062149714 @default.
• W2912103211 creator A5063591215 @default.
• W2912103211 creator A5067237537 @default.
• W2912103211 creator A5067347864 @default.
• W2912103211 creator A5076961983 @default.
• W2912103211 creator A5078318313 @default.
• W2912103211 creator A5084326780 @default.
• W2912103211 creator A5089865834 @default.
• W2912103211 date "2019-05-14" @default.
• W2912103211 modified "2023-10-15" @default.
• W2912103211 title "Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight" @default.
• W2912103211 cites W2057179512 @default.
• W2912103211 cites W2073493628 @default.
• W2912103211 cites W2096246254 @default.
• W2912103211 cites W2097854437 @default.
• W2912103211 cites W2107832644 @default.
• W2912103211 cites W2116532362 @default.
• W2912103211 cites W2118857793 @default.
• W2912103211 cites W2130340163 @default.
• W2912103211 cites W2136489990 @default.
• W2912103211 cites W2162508946 @default.
• W2912103211 cites W2166402206 @default.
• W2912103211 cites W2311379003 @default.
• W2912103211 cites W2337286163 @default.
• W2912103211 cites W2485673570 @default.
• W2912103211 cites W2594312574 @default.
• W2912103211 cites W2597608277 @default.
• W2912103211 cites W2606391344 @default.
• W2912103211 cites W2762376214 @default.
• W2912103211 cites W2784513652 @default.
• W2912103211 doi "https://doi.org/10.1161/circulationaha.118.037955" @default.
• W2912103211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30773022" @default.
• W2912103211 hasPublicationYear "2019" @default.
• W2912103211 type Work @default.
• W2912103211 sameAs 2912103211 @default.
• W2912103211 citedByCount "65" @default.
• W2912103211 countsByYear W29121032112019 @default.
• W2912103211 countsByYear W29121032112020 @default.
• W2912103211 countsByYear W29121032112021 @default.
• W2912103211 countsByYear W29121032112022 @default.
• W2912103211 countsByYear W29121032112023 @default.
• W2912103211 crossrefType "journal-article" @default.
• W2912103211 hasAuthorship W2912103211A5006527198 @default.
• W2912103211 hasAuthorship W2912103211A5009430890 @default.
• W2912103211 hasAuthorship W2912103211A5014449865 @default.
• W2912103211 hasAuthorship W2912103211A5015603706 @default.
• W2912103211 hasAuthorship W2912103211A5027138068 @default.
• W2912103211 hasAuthorship W2912103211A5036973667 @default.
• W2912103211 hasAuthorship W2912103211A5062149714 @default.
• W2912103211 hasAuthorship W2912103211A5063591215 @default.
• W2912103211 hasAuthorship W2912103211A5067237537 @default.
• W2912103211 hasAuthorship W2912103211A5067347864 @default.
• W2912103211 hasAuthorship W2912103211A5076961983 @default.
• W2912103211 hasAuthorship W2912103211A5078318313 @default.
• W2912103211 hasAuthorship W2912103211A5084326780 @default.
• W2912103211 hasAuthorship W2912103211A5089865834 @default.
• W2912103211 hasBestOaLocation W29121032111 @default.
• W2912103211 hasConcept C126322002 @default.
• W2912103211 hasConcept C127413603 @default.
• W2912103211 hasConcept C164705383 @default.
• W2912103211 hasConcept C168563851 @default.
• W2912103211 hasConcept C2776301958 @default.
• W2912103211 hasConcept C2776704044 @default.
• W2912103211 hasConcept C2778661090 @default.
• W2912103211 hasConcept C2779161974 @default.
• W2912103211 hasConcept C2780638905 @default.
• W2912103211 hasConcept C2780645631 @default.
• W2912103211 hasConcept C42219234 @default.
• W2912103211 hasConcept C500558357 @default.
• W2912103211 hasConcept C71924100 @default.
• W2912103211 hasConcept C78519656 @default.
• W2912103211 hasConceptScore W2912103211C126322002 @default.
• W2912103211 hasConceptScore W2912103211C127413603 @default.
• W2912103211 hasConceptScore W2912103211C164705383 @default.
• W2912103211 hasConceptScore W2912103211C168563851 @default.
• W2912103211 hasConceptScore W2912103211C2776301958 @default.
• W2912103211 hasConceptScore W2912103211C2776704044 @default.
• W2912103211 hasConceptScore W2912103211C2778661090 @default.
• W2912103211 hasConceptScore W2912103211C2779161974 @default.
• W2912103211 hasConceptScore W2912103211C2780638905 @default.
• W2912103211 hasConceptScore W2912103211C2780645631 @default.
• W2912103211 hasConceptScore W2912103211C42219234 @default.
• W2912103211 hasConceptScore W2912103211C500558357 @default.
• W2912103211 hasConceptScore W2912103211C71924100 @default.
• W2912103211 hasConceptScore W2912103211C78519656 @default.
• W2912103211 hasIssue "20" @default.
• W2912103211 hasLocation W29121032111 @default.
• W2912103211 hasLocation W29121032112 @default.
• W2912103211 hasLocation W29121032113 @default.
• W2912103211 hasOpenAccess W2912103211 @default.

• next